Efficacy of second-line therapies for SMARCA4-mutated NSCLC based on a nationwide comprehensive genomic profiling database
Background: Clinical data on existing therapies for SMARCA4-mutated tumors are scarce, hindering the development of new agents targeting these mutations.
Authors
- Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0001-8787-5587)
- Takayuki Takahama (ORCID: https://orcid.org/0000-0002-0321-6718)
- Daiki Murata (ORCID: https://orcid.org/0000-0002-4295-5046)
Institutions
- Kindai University (JP)
Publication Details
- Journal
- iScience
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1016/j.isci.2026.118256
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00